An interventional study of Sodium fluoride (1426 ppm) and Sodium fluoride (1150 ppm) in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-01.
Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the effect of experimental sodium fluoride-silica dentifrice formulations, with and without zinc, on remineralization of enamel in situ. Following the remineralization phase, the acid resistance of the new mineral formed will be assessed. Fluoride uptake during the remineralization phase will also be measured.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
Drug: Sodium fluoride (1426 ppm)
Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
Drug: Sodium fluoride (1150 ppm)
Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
Drug: Sodium fluoride (250 ppm)
Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
Drug: Sodium fluoride (1426 ppm) + zinc base A
Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
Drug: Sodium fluoride (1426 ppm) + zinc base B
Non-zinc, 0ppm fluoride in a silica gel base
Drug: Fluoride (0 ppm)
Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
Non-zinc, 0ppm fluoride in a silica gel base
Percentage Surface Microhardness Recovery (% SMHR)
Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the Surface Microhardness (SMH) Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was determined prior to the in vitro acid challenge. SMH was determined again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The extent of remineralization was calculated as the % recovery in SMH using the equation: % SMHR= \[(D1-R)/(D1-B)\]\*100 Where B = indentation length (μm) of sound enamel at baseline; D1 = indentation length (μm) after first acid challenge; R = indentation length (μm) after in situ remineralization.
Time frame: Baseline to 4 hours
Enamel Fluoride Uptake
The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling sample was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm\^2).
Time frame: Baseline to 4 hours
Percentage Net Acid Resistance (% NAR)
Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % NAR was calculated using the equation: % NAR= \[(D1-D2)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; D1= Indentation length (μm) after first acid challenge and D2= Indentation length (μm) after second acid challenge.
Time frame: Baseline to 4 hours
Percentage Comparative Acid Resistance (% CAR)
Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % CAR was calculated using the equation: % CAR= \[(D2-R)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; R= Indentation length (μm) of enamel after in situ remineralization; D1= Indentation length (μm) after first acid challenge; D2= Indentation length (μm) after second acid challenge.
Time frame: Baseline to 4 hours
Participants were recruited at one clinical study site in the USA.
| Milestone | Overall Participants |
|---|---|
| Started | 62 |
| Sodium fluoride (1150 ppm) | 57 |
| Sodium fluoride (0 ppm) | 59 |
| Sodium fluoride (1426 ppm) + zinc base a | 58 |
| Sodium fluoride (250 ppm) | 55 |
| Sodium fluoride (1426 ppm) | 59 |
| Sodium fluoride (1426 ppm) + zinc base b | 60 |
| Completed | 53 |
| Not completed | 9 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 2 |
| Withdrew: Other reason | 2 |
Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the Surface Microhardness (SMH) Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was determined prior to the in vitro acid challenge. SMH was determined again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The extent of remineralization was calculated as the % recovery in SMH using the equation: % SMHR= \[(D1-R)/(D1-B)\]\*100 Where B = indentation length (μm) of sound enamel at baseline; D1 = indentation length (μm) after first acid challenge; R = indentation length (μm) after in situ remineralization.
| Percentage of SMHR | Sodium Fluoride (1426 Ppm) | Sodium Fluoride (1150 Ppm) | Sodium Fluoride (250 Ppm) | Sodium Fluoride (1426 Ppm) + Zinc Base A | Sodium Fluoride (1426 Ppm) + Zinc Base B | Sodium Fluoride (0 Ppm) |
|---|---|---|---|---|---|---|
| Percentage Surface Microhardness Recovery (% SMHR) | 32.49 ± 1.167 | 31.81 ± 1.182 | 27.56 ± 1.199 | 22.62 ± 1.175 | 23.22 ± 1.159 | 24.78 ± 1.167 |
The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling sample was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm\^2).
| microgram per square centimeter(μg/cm^2) | Sodium Fluoride (1426 Ppm) | Sodium Fluoride (1150 Ppm) | Sodium Fluoride (250 Ppm) | Sodium Fluoride (1426 Ppm) + Zinc Base A | Sodium Fluoride (1426 Ppm) + Zinc Base B | Sodium Fluoride (0 Ppm) |
|---|---|---|---|---|---|---|
| Enamel Fluoride Uptake | 2.94 ± 0.083 | 2.70 ± 0.084 | 1.85 ± 0.085 | 2.62 ± 0.083 | 2.37 ± 0.082 | 0.98 ± 0.083 |
Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % NAR was calculated using the equation: % NAR= \[(D1-D2)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; D1= Indentation length (μm) after first acid challenge and D2= Indentation length (μm) after second acid challenge.
| Percentage of NAR | Sodium Fluoride (1426 Ppm) | Sodium Fluoride (1150 Ppm) | Sodium Fluoride (250 Ppm) | Sodium Fluoride (1426 Ppm) + Zinc Base A | Sodium Fluoride (1426 Ppm) + Zinc Base B | Sodium Fluoride (0 Ppm) |
|---|---|---|---|---|---|---|
| Percentage Net Acid Resistance (% NAR) | -12.54 ± 1.224 | -13.45 ± 1.244 | -17.81 ± 1.266 | -17.60 ± 1.234 | -18.98 ± 1.214 | -50.60 ± 1.224 |
Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % CAR was calculated using the equation: % CAR= \[(D2-R)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; R= Indentation length (μm) of enamel after in situ remineralization; D1= Indentation length (μm) after first acid challenge; D2= Indentation length (μm) after second acid challenge.
| Percentage of CAR | Sodium Fluoride (1426 Ppm) | Sodium Fluoride (1150 Ppm) | Sodium Fluoride (250 Ppm) | Sodium Fluoride (1426 Ppm) + Zinc Base A | Sodium Fluoride (1426 Ppm) + Zinc Base B | Sodium Fluoride (0 Ppm) |
|---|---|---|---|---|---|---|
| Percentage Comparative Acid Resistance (% CAR) | 45.00 ± 1.274 | 45.23 ± 1.295 | 45.44 ± 1.319 | 40.29 ± 1.285 | 42.21 ± 1.264 | 75.41 ± 1.274 |
Collected over Adverse Events (AEs) were collected from the start of the investigational product (or washout product) and until five days following last administration of the investigational product.Serious adverse events (SAEs) were collected over the same time period.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Fluoride (1426 Ppm) | — | 0/59 (0%) | 3/59 (5.1%) |
| Sodium Fluoride (1150 Ppm) | — | 0/57 (0%) | 1/57 (1.8%) |
| Sodium Fluoride (250 Ppm) | — | 0/55 (0%) | 5/55 (9.1%) |
| Sodium Fluoride (1426 Ppm) + Zinc Base A | — | 0/58 (0%) | 1/58 (1.7%) |
| Sodium Fluoride (1426 Ppm) + Zinc Base B | — | 1/60 (1.7%) | 4/60 (6.7%) |
| Sodium Fluoride (0 Ppm) | — | 0/59 (0%) | 5/59 (8.5%) |
| Event | Sodium Fluoride (1426 Ppm) | Sodium Fluoride (1150 Ppm) | Sodium Fluoride (250 Ppm) | Sodium Fluoride (1426 Ppm) + Zinc Base A | Sodium Fluoride (1426 Ppm) + Zinc Base B | Sodium Fluoride (0 Ppm) |
|---|---|---|---|---|---|---|
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/59 | 0/57 | 0/55 | 0/58 | 1/60 | 0/59 |
| Event | Sodium Fluoride (1426 Ppm) | Sodium Fluoride (1150 Ppm) | Sodium Fluoride (250 Ppm) | Sodium Fluoride (1426 Ppm) + Zinc Base A | Sodium Fluoride (1426 Ppm) + Zinc Base B | Sodium Fluoride (0 Ppm) |
|---|---|---|---|---|---|---|
| Oral Mucosal ErythemaGastrointestinal disorders | 2/59 | 0/57 | 0/55 | 0/58 | 1/60 | 2/59 |
| Abdominal DiscomfortGastrointestinal disorders | 0/59 | 0/57 | 1/55 | 0/58 | 0/60 | 0/59 |
| NasopharyngitisInfections and infestations | 0/59 | 0/57 | 1/55 | 0/58 | 1/60 | 1/59 |
| HeadacheNervous system disorders | 0/59 | 0/57 | 1/55 | 0/58 | 0/60 | 0/59 |
| PalpitationsCardiac disorders | 0/59 | 0/57 | 1/55 | 0/58 | 0/60 | 0/59 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 0/59 | 0/57 | 1/55 | 0/58 | 0/60 | 0/59 |
| DysmenorrhoeaReproductive system and breast disorders | 0/59 | 1/57 | 0/55 | 0/58 | 0/60 | 0/59 |
| Motion sicknessEar and labyrinth disorders | 0/59 | 0/57 | 0/55 | 1/58 | 0/60 | 0/59 |
| Lymph gland infectionInfections and infestations | 1/59 | 0/57 | 0/55 | 0/58 | 0/60 | 0/59 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/59 | 0/57 | 0/55 | 0/58 | 0/60 | 1/59 |
All randomized participants were evaluated for baseline characteristics
| Age, Continuous(Years) | All Randomized Participants |
|---|---|
| Mean | 40.7 ± 12.03 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 39 |
| Male | 23 |
The record gives a start of Jun 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Fluoride